Patients with vs without nonarteritic anterior ischemic optic neuropathy demonstrated an elevated risk for stroke. Individuals with vs without nonarteritic anterior ischemic optic neuropathy (NAION) ...

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy. HealthDay ...

Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec.

Semaglutide exposure was significantly associated with a higher incidence rate and independently predicted a higher risk for upcoming nonarteritic anterior ischemic optic neuropathy, even when ...

Findings were seen for patients with type 2 diabetes during a 5-year period. HealthDay News — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...

An increased risk for NAION was seen among participants with T2D, overweight/obesity receiving semaglutide vs non-GLP1-RA meds. Jimena Tatiana Hathaway, M.D., M.P.H., from the Harvard T.H. Chan ...

Findings seen for patients with type 2 diabetes during a 5-year period. (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic ...

TUESDAY, Jan. 14, 2025 (HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, ...

Methods Patients with acute anterior ischemic stroke undergoing endovascular treatment between April 2015 and November 2019 were retrospectively analyzed. Only patients with premorbid modified Rankin ...

(HealthDay News) — Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study ...